Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine Plus Cisplatin in Refractory Germ Cell Tumors
NCT02429466Phase 1Completed
- Sponsor
- Nasser Hanna
- Start
- Apr 2015
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guadecitabine in germ cell tumor (GCT), sponsored by Nasser Hanna. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Started Apr 2015; status: completed.
02
Drugs
guadecitabine
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02429466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429466.